Townsquare Capital LLC Decreases Position in argenx SE (NASDAQ:ARGX)

Townsquare Capital LLC trimmed its holdings in shares of argenx SE (NASDAQ:ARGX) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,261 shares of the company’s stock after selling 46 shares during the quarter. Townsquare Capital LLC’s holdings in argenx were worth $2,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in ARGX. Steward Partners Investment Advisory LLC grew its holdings in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after buying an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its position in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC grew its stake in argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC increased its holdings in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Finally, Choreo LLC increased its holdings in shares of argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after purchasing an additional 23 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

argenx stock opened at $605.38 on Wednesday. The firm has a market capitalization of $36.78 billion, a PE ratio of -687.93 and a beta of 0.60. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock’s 50 day moving average price is $605.51 and its 200 day moving average price is $604.95.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ARGX shares. Guggenheim boosted their target price on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Piper Sandler boosted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Robert W. Baird boosted their price target on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Finally, Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.